Tofacitinib Delay May Give FDA Time To Look At New Radiographic Data
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA has extended the review deadline to look over requested data on tofacitinib, but Pfizer is also interested in turning over an interim analysis of the ORAL Start study, which provides radiographic evidence of tofacitinib’s structural benefit in rheumatoid arthritis, a weak point in the NDA.